Bronchospasm: causes, signs, treatment and clinical considerations

Mechanism and underlying changes

The core event in bronchospasm is bronchial smooth muscle contraction accompanied often by mucosal swelling and increased mucus secretion. Chemical mediators released from immune cells — notably mast cells or basophils in allergic reactions — can provoke muscle constriction and inflammation. The muscular tightening occurs in the walls of the smaller airways (bronchioles), where even modest narrowing has a large effect on airflow because of their small diameter.

Common triggers and contributing factors

• Asthma: the most frequent long-term condition associated with episodic bronchospasm, often driven by allergic or nonallergic airway hyperresponsiveness.
• Chronic bronchitis and other chronic obstructive pulmonary diseases, where inflammation and airway remodeling increase susceptibility.
• Anaphylaxis and other severe allergic reactions, which can cause rapid, generalized bronchospasm alongside cardiovascular effects.
• Inhaled irritants (smoke, pollution, chemical fumes), respiratory infections, cold air, exercise-induced bronchospasm, and certain medications or foods in sensitive individuals.
• Procedural causes such as airway manipulation during intubation or suctioning in anaesthesia or critical care settings; these are recognized risks that can precipitate sudden bronchospasm.

Clinical features and diagnosis

Typical symptoms include audible wheeze, labored breathing, cough and reduced exercise tolerance. On examination, clinicians may note prolonged expiratory phase and diffuse wheeze. Objective testing can document airflow limitation: peak expiratory flow measurements and spirometry may show reduced expiratory flows that often improve with bronchodilator therapy. In some patients bronchial provocation testing is used to assess airway hyperresponsiveness, while severe episodes are assessed and monitored with pulse oximetry and arterial blood gas when necessary.

Treatment and acute management

Initial treatment aims to reopen the airway and correct oxygenation. Short-acting inhaled beta2-agonists (for example salbutamol) are first-line for most acute episodes; inhaled anticholinergics (ipratropium) may be added. Systemic corticosteroids are commonly used to reduce airway inflammation when bronchospasm is moderate to severe or prolonged. In life-threatening allergic bronchospasm or anaphylaxis, intramuscular or intravenous epinephrine is indicated. Oxygen supplementation and airway support, including mechanical ventilation, are reserved for patients with significant hypoxaemia or respiratory failure.

Prevention, clinical considerations and prognosis

Long-term prevention in recurrent cases focuses on identifying and avoiding triggers, using controller medications where appropriate (inhaled corticosteroids, long-acting bronchodilators) and optimizing inhaler technique. In procedural settings, preoperative assessment and prophylactic bronchodilator therapy may reduce the risk of bronchospasm during airway manipulation. Many episodes respond well to prompt treatment, but severe or untreated bronchospasm can cause respiratory compromise; timely recognition and management are therefore important.

For more clinical guidance and patient information see resources linked here: airway anatomy and bronchioles, immune cell roles in allergy, asthma management, chronic bronchitis overview and anaphylaxis protocols.